Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2024-2030

Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2024-2030

The Travel Vaccines Market size was estimated at USD 8.26 billion in 2023 and expected to reach USD 9.09 billion in 2024, at a CAGR 10.06% to reach USD 16.18 billion by 2030.

The travel vaccines market encompasses the production, distribution, and administration of immunizations recommended or required for international travelers based on specific regional disease risk exposures. The ongoing growth in the travel vaccines market is primarily driven by increased international travel, rising awareness about vaccine-preventable diseases, and governmental travel regulations mandating certain vaccines for entry. Additionally, the expansion of the global tourism industry and proactive health measures by international travelers fuel the demand for travel vaccines. Technological advancements in vaccine storage and stability contribute to market growth by enabling wider vaccine accessibility and distribution. The major challenges affecting the growth of the travel vaccines market include high costs associated with vaccine development and strict regulatory requirements leading to prolonged approval times. Additionally, the limited shelf life of vaccines, cold chain logistics requirements, and vaccine hesitancy among specific traveler demographics further impede market growth. Emerging market opportunities include developing vaccines against evolving infectious disease threats and expanding the existing travel vaccine portfolio to include neglected tropical diseases. An increase in public-private partnerships for vaccine research and development and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders represent significant prospects for industry expansion.

Regional Insights

In the Americas, the United States and Canada represent significant markets for travel vaccines, driven by high outbound travel rates and robust healthcare infrastructure. Consumer behavior shows a high degree of awareness and preparedness for travel health, leading to a steadfast demand for vaccines against diseases such as Yellow Fever, Typhoid, and Hepatitis A and B. The European Union exhibits a robust travel vaccine market due to well-established healthcare systems and high travel frequency to regions with vaccine-preventable diseases. The EU's streamlined regulatory framework fosters a conducive environment for introducing new vaccines. The Middle East & Africa region presents a varied landscape for travel vaccines, with the Gulf Cooperation Council countries showing growing demand due to increasing travel and healthcare investments. The Asia Pacific region is witnessing rapid growth in the travel vaccine market, with China, Japan, and India leading the way for market expansion. Notably, China and India invest heavily in vaccine R&D to become self-sufficient in vaccine production. Japan's market is distinguished by high consumer awareness and advanced vaccine technology, supported by government-led immunization campaigns.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Travel Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing Popularity of International Tourism
• Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
• Recent Investments and Improvement in Cold Chain Storage Infrastructure

Market Restraints

• Limited Awareness Amongst Travelers

Market Opportunities

• Innovations in Novel Vaccine Technologies and Advancements
• Government and Organizational Funding and Initiatives for Immunization and Vaccine Development

Market Challenges

• Issues Related to Vaccine Handling and Storage

Market Segmentation Analysis

• Type: Advancements in DNA vaccines to induce immune response
• Disease: Need based preference for hepatitis vaccines among travelers

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Travel Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Travel Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad

The Indian Immunologicals Limited (IIL) has launched Havisure, the nation’s first indigenously developed vaccine against Hepatitis A. This highly contagious liver infection, primarily transmitted through the fecal-oral route via contaminated food or water, represents a substantial public health concern. Through rigorous clinical testing across eight centers, Havisure has demonstrated its safety and efficacy, showcasing results on par with the leading global vaccines

FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

Pfizer Inc. has achieved a significant milestone in public health with the U.S. Food and Drug Administration (FDA)'s approval of PENBRAYA, the inaugural pentavalent vaccine offering comprehensive protection against the predominant serogroups (A, B, C, W, and Y) responsible for causing meningococcal disease among adolescents and young adults aged 10 through 25. This innovative vaccine merges the strengths of Trumenba and Nimenrix, targeting the five key serogroups linked to the majority of invasive meningococcal disease (IMD) instances globally.

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Pfizer Inc. and BioNTech SE have announced the approval from the U.S. Food and Drug Administration (FDA) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, tailored for the 2023-2024 flu season. This approval encompasses a supplemental Biologics License for those aged 12 and older, alongside an emergency use authorization for ages 6 months to 11 years. This updated vaccine, recommended for a single dose in individuals 5 years and up—with particular dosing guidelines for children under 5—aims to fortify protection against the evolving COVID-19 variants, especially the predominant Omicron XBB-related sublineages.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Travel Vaccines Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, Biological E Limited, Cadila Pharmaceuticals Limited, CSL Limited, Dano Vaccines & Biologicals Private Limited, Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Indian Immunologicals Ltd., Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
• Attenuated Vaccines
• Conjugate Vaccines
• DNA Vaccines
• Inactive Vaccines
• Recombinant Vector Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Disease
• DPT
• Hepatitis A
• Hepatitis B
• Japanese Encephalitis
• Measles and Mumps
• Meningococcal
• Rabies
• Typhoid
• Varicella
• Yellow Fever
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year